Evidence map›Paper›PMID 38034171›Full record

ArticleCureus2023

The Administration of Levodopa in a Patient With Parkinson's Disease Using a Novel Maxillofacial Route: A First-in-Human Report.

Suresh Thirunavukarasu, Balasubramanian Bala Venkata Ramanan, Sathya Krishnan Suresh, Vincent Jayakumar Antonisamy, Devi Varadharaj, Paranjothi Shanmugam, Kavita Verma, Canmany Elumalai, Gladson Selvakumar, Ahila Elumalai and 3 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Suresh ThirunavukarasuNeurology, Indira Gandhi Government General Hospital and Post Graduate Institute, Puducherry, IND.
Balasubramanian Bala Venkata RamananNeurology, Indira Gandhi Government General Hospital and Post Graduate Institute, Puducherry, IND.
Sathya Krishnan SureshComputer Science Engineering, Puducherry Technological University, Puducherry, IND.
Vincent Jayakumar AntonisamyGeneral Medicine, Indira Gandhi Government General Hospital and Post Graduate Institute, Puducherry, IND.
Devi VaradharajNeurology, Indira Gandhi Government General Hospital and Post Graduate Institute, Puducherry, IND.
Paranjothi ShanmugamNeurology, Indira Gandhi Government General Hospital and Post Graduate Institute, Puducherry, IND.
Kavita VermaResearch and Development, UR Anoop Research Group, Puducherry, IND.
Canmany ElumalaiOrthodontics and Dentofacial Orthopaedics, UR Anoop Research Group, Puducherry, IND.
Gladson SelvakumarConservative Dentistry and Endodontics, UR Anoop Research Group, Puducherry, IND.
Ahila ElumalaiPeriodontics, UR Anoop Research Group, Puducherry, IND.
Lydia PrabaharDentistry, UR Anoop Research Group, Puducherry, IND.
Hridwik Adiyeri JanardhananResearch and Development, UR Anoop Research Group, Puducherry, IND.
Anoop UrResearch and Development, UR Anoop Research Group, Puducherry, IND.
Pondicherry University · INGovernment General Hospital · INITPEnergised Group (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is characterized by the loss of nigrostriatal dopaminergic neurons in the brain. Dopamine cannot be administered systemically because it does not cross the blood-brain barrier. Oral levodopa remains the gold standard to date. Currently, for patients who show a poor response to oral levodopa and for those who cannot take it orally, the alternate routes available are inhalation and continuous administration via intestinal and subcutaneous routes. In this report, a novel maxillofacial route was used for the first time in the world to administer levodopa to a Parkinson's patient. Furthermore, the efficacy of maxillofacial administration was compared with the oral route of administration.

Indexed as

drug delivery systemlevodopamaxillofacial routenovel drug deliveryparkinson' s disease

Identifiers

PMID38034171
PMCPMC10687491
OpenAlexW4388044288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.